Risk factors for unlicensed and off-label drug use in children outside the hospital

Pediatrics

Volumn 111, Issue 2, 2003, Pages 291-295

  Schirm, Eric ^a   Tobi, Hilde ^a,c   De Jong Van den Berg, Lolkje T W ^a,b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b InterAction Working Group   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Children; Drug utilization; Off label; Pediatrics; Pharmacy dispensing data; Unlicensed

Indexed keywords

ANALGESIC AGENT; ANTIASTHMATIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIMIGRAINE AGENT; ANTIPYRETIC ANALGESIC AGENT; ANTITUSSIVE AGENT; ANTIULCER AGENT; ANXIOLYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; CEPHALOSPORIN DERIVATIVE; CORTICOSTEROID; DERMATOLOGICAL AGENT; DIURETIC AGENT; GASTROINTESTINAL AGENT; HYPNOTIC SEDATIVE AGENT; INSULIN; LAXATIVE; MACROLIDE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN DERIVATIVE; PSYCHOSTIMULANT AGENT; SULFONAMIDE; TETRACYCLINE; TRIMETHOPRIM; UNINDEXED DRUG;

ADOLESCENT; ARTICLE; CARDIOVASCULAR DISEASE; CHILD; CHILDHOOD DISEASE; DIABETES MELLITUS; DRUG FORMULATION; DRUG LABELING; DRUG MARKETING; DRUG USE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; HUMAN; INFANT; INFECTION; MAJOR CLINICAL STUDY; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT; RESPIRATORY TRACT DISEASE; RISK FACTOR; SKIN DISEASE;

ADOLESCENT; CHILD; CHILD, HOSPITALIZED; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DRUG AND NARCOTIC CONTROL; DRUG APPROVAL; DRUG LABELING; FAMILY PRACTICE; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LEGISLATION, DRUG; LICENSURE; MALE; NETHERLANDS; PHARMACEUTICAL PREPARATIONS; PHARMACEUTICAL SERVICES; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; RISK FACTORS;

EID: 0037317932     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.111.2.291     Document Type: Article

References (22)

1. Wilson JT. An Update on the therapeutic orphan. Pediatrics. 1999; 104(suppl):585-590
2. Impicciatore P, Choonara I. Status of new medicines approved by the European Medicines Evaluation Agency regarding paediatric use. Br J Clin Pharmacol. 1999;48:15-18
3. Turner S, Longworth A, Nunn AJ, Choonara I. Unlicensed and off-label drug use in paediatric wards: prospective study. BMJ. 1998;318:343-345
4. 't Jong GW, Vulto AG, De Hoog M, Schimmel K, Tibboel D, Van den Anker JN. Unapproved and off-label use of drugs in a children's hospital. N Engl J Med. 2000;343:1125
5. Turner S, Gill G, Nunn T, Hewitt B, Choonara I. Use of "off-label" and unlicensed drugs in paediatric intensive care unit. Lancet. 1996;347: 549-550
6. Conroy S, McIntyre J, Choonara I. Unlicensed and off-label drug use in neonates. Arch Dis Child Fetal Neonatal Ed. 1999;80:F142-F145
7. Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off-label drug use in paediatric wards in European countries. BMJ. 2000;320:79-82
8. 't Jong GW, Vulto AG, De Hoog M, Schimmel K, Tibboel D, Van den Anker JN. A survey of the use of off-label and unlicensed drugs in a Dutch children's hospital. Pediatrics. 2001;108:1089-1093
9. Chalumeau M, Tréluyer JM, Salanave B, et al. Off-label and unlicensed drug used among French office based paediatricians. Arch Dis Child. 2000;83:502-505
10. McIntyre J, Conroy S, Avery A, Corns H, Choonara I. Unlicensed and off-label prescribing of drugs in general practice. Arch Dis Child. 2000; 83:498-501
11. Schirm E, Tobi H, De Jong-van den Berg LTW. A cross-sectional study on unlicensed and off-label drug use by children outside the hospital. BMJ. 2002;324:1312-1313
12. De Jong-van den Berg LTW, Feenstra N, Toft Sorensen H, Cornel MC, EuroMAP group. Improvement of drug exposure data in a registration of congenital anomalies. Pilot study: pharmacist and mother as sources for drug exposure data during pregnancy. Teratology. 1999;60:33-36
13. Lau HS, De Boer A, Beuning KS, Porsius A. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol. 1997;50:619-625
14. Tobi H, Van den Berg PB, De Jong-van den Berg LTW. The InterAction database: synergy of science and practice in pharmacy. In: Brause RW, Hanisch E, eds. Medical Data Analysis. Lecture Notes in Computer Sciences (1933). Frankfurt, Germany: Springer; 2000:206-211
15. WHO Collaborating Centre for Drug Statistic Methodology. Guidelines for ATC Classification and DDD Assignment. Oslo, Norway: World Health Organization; 1999
16. Stichting Farmaceutische Kengetallen. Farmacie in cijfers. Minder bereidingen in de apotheek [Pharmacy figures. Less pharmacy-based preparations]. Pharm Weekbl. 200;136:619
17. Metry DW, Hebert AA. Topical therapies and medications in the pediatric patient. Pediatr Clin North Am. 2000;47:867-876
18. Needlman RD. Growth and development. In: Behrman RE, Kliegman RM, Arvin AM, Nelson WE, eds. Nelson Textbook of Paediatrics. 15th ed. Philadelphia, PA: WB Saunders; 1996:30-72
19. Autret E. European regulatory authorities and pediatric labeling. Pediatrics. 1999;104(suppl):614-618
20. Banner W. Off label prescribing in children. A view from the United States. BMJ. 2002;324:1290-1291
21. US Food and Drug Administration. The Pediatric Exclusivity Provision. Status Report to Congress. Rockville, MD, January 2001. Available at: www.fda.gov/cder/pediatric/reportcong01.pdf. Accessed Jul 25, 2002
22. European Commission. Better Medicines for Children. Proposed regulatory actions on paediatric medicinal products. Brussels, February 2002. Available at: pharmacos.eudra.org/F2/pharmacos/docs/Doc2002/feb/cd_pediatrics_en.pdf. Accessed Jul 25, 2002